* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Drug information - Millennium Organization
Neuropharmacology wikipedia , lookup
Drug design wikipedia , lookup
Pharmacognosy wikipedia , lookup
Compounding wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Prescription costs wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Introduction to the Concept of Medication Information What is drug information ? • It has different meanings to different people depending on the context in which it is used. • information printed in a reference. • verbalized by an individual that pertains to drugs. • medication information. • The provision of medication information is among the most fundamental responsibilities of pharmacists. Drug information specialist must be: 1- individual responsible for operating the center 2- capable of storing information in the center and retrieve, select and distribute it to: a-respond to specific questions, b- help evaluation of drugs for use in the hospital, c- inform through newsletters of current developments related to drugs Information may be: • Patient specific, as an integral part of pharmaceutical care, or • relative to a group of patients, such as in the context of a disease management program or publishing in a newsletter. The Beginning • In 1962, the first drug information center opened at the University of Kentucky Medical Center. • to evaluate , compare drugs, and provide the drug information for : staff physicians , dentists and nurses. education of health professional students including medicine, dentistry, nursing, and pharmacy. The goal was to influence pharmacy students in developing their role as drug consultants. i- Decentralizing pharmacists ii- Offering a clinical consultation service iii- Providing services for a geographic area through a regional center. The development of drug information centers and drug information specialists was the beginning of the clinical pharmacy concept. Medication Information Services 1- Support for clinical services i- Answering questions ii- Developing principle guidelines for medication use 2- Pharmacy and therapeutics committee activity (P & T committee). i- Development of medication use policies ii- Formulary management 3- Publications-newsletter, journal columns. 4- Education-services (health professionals & students). 5. Medication usage (practice, procedure, handle) evaluation/ medication use (spend) evaluation 6. Investigational medication control i. Institutional Review Board activities (IRBs) IRBs are responsible for ensuring that research ethics are followed in each institution ii. Information for practitioners 7. Coordination of reporting programs e.g., adverse medication reactions 8. Poison information 9. Expert testimony. Development of information provision 1- The Medical Literature Retrieval and Analysis System (MEDRALS) was developed by the National Library of Medicine in the early 1960s. Although it provided a computerized form of searching, requests for searches were submitted by mail and results returned by mail. 2- The ability to transmit such information over telephone lines (on-line technology) was not available until 1971 when MEDLINE was introduced and was limited to libraries. 3- Nowadays information is easily provided through telephones and online connections. The Evolution • Majority of centers (>80%) are located in hospitals • few (7%) are located in colleges of pharmacy. • 70% of which have primarily educational purposes. The responsibilities of individual pharmacists regarding the provision of drug information have changed substantially over the years. • Motivation for this change includes: 1- drug information centers and the clinical pharmacy concept. 2- Study commission on Pharmacy External official group or committee was established to review the state of the practice and education of pharmacists and report its findings. • Pharmaceutical care term has broaden the concept to involve patients in any environment not only hospitals: • It is defined as “the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient’s quality of life.” • Pharmacists involved in patient care areas (e.g., hospitals, clinics, long-term care, home health care) answer drug information questions, participate in evaluating a patient’s drug therapy, and carry out medication usage evaluation activities. • The provision of medication information may be 1- on a one-on-one basis or 2- may occur using a more structured approach, such as a presentation to a class of diabetic patients or a group of nurses in the practice facility. Pharmacists in Community Settings 1. Counsel patients 2. Answer drug information questions 3. Review patient medication regimens for potential problems 4. Participate in helping patients manage their chronic diseases. Factors Influencing the Evolution of the Pharmacist’s Role as a Medication Information Provider 1. Growth of information technology 2. Changes in the health care environment with focus on evidencebased medicine and evaluation of outcomes 3. The sophistication of medication therapy 4. More knowledgeable patient 1- Integration of New Technologies • Computer technology has changed drastically, however, storing and retrieving data has become more manageable. • The internet & World Wide Web provide a tool for sharing information & allow the user to have easily access to the scientific literature, government publications, items in the news, etc……. • The information may be in textual form, or include graphics, video, or sound. • Pharmacist in a local community pharmacy or rural hospital can communicate with health care professionals or their patients locally or get medical data found in another country. • These techniques also ease the access to the patient’s medical records. • Local area networks (LAN), palm top computers search drug information data bases as Physician’s Desk Reference (PDR). • All this technology & information need skilled pharmacist. 2- Evidence-Based Medicine and Drug Policy Development • Evidence-Based Medicine is an approach to practice and teaching that connect current clinical research evidence with pathophysiologic basis, professional expertise, and patient preferences. • Evidence-Based Medicine techniques are used in the development of therapeutic guidelines, clinical pathways, medication use evaluations, and disease state management. • Emphasizes the need for skilled pharmacist with solid understanding of drug information concepts and be able to evaluate the medication use issues for a group of patients, be able to search, retrieve, and critically evaluate the scientific literature, and apply the information to the targeted group of patients. • All the drug analysis processes help to support the decision making process in a managed care organization, where the outcomes can be used to identify the effectiveness of pharmaceutical products and evaluate pharmacoeconomics (cost, consequences, and efficiency) to help services in achieving desired health outcomes. 3- Sophistication of Medication Therapy •It is increasingly difficult for physicians & other health professionals to keep up with all of the developments in medication therapy, & keep this side by side to the required information for their practice. •Sophisticated level of medication therapy offers pharmacists opportunity to assess the medication information needs of professionals, patients, or family members. • Pharmacists can provide literature to: a- differentiate the choice of medications within a class, b- suggest the appropriate information to help patients correctly and safely by using more potent medications, & address administration and delivery problems to avoid medication therapy problems. 4- Consumerism • Consumers have a growing desire for information about their medications. ! increase in improved growth of focus on accessibility the selfhealth care of health care costs information movement •These are some factors that have influenced patients to participate more fully in health care decisions, including the selection and use of medications. • Based on these needs, direct-to-consumer advertising (DTCA) campaigns have appeared in virtually all mediums including magazines, television, and radio. Gps as National Council on Patient Information and Education (NCPIE) • “Medication information hotlines” established by pharmacists, enhance the relationships between pharmacists, physicians, and patients, the 3 Ps. Poison Control • Poison information is a specialized area of medication information with the practitioner typically practicing in an accredited poison information center or an emergency room. • Its mission is to provide accurate and timely information to enhance the quality of care of patients. • In the P.I.C. most consultations are generated from the public, while in DIC the health professionals generate most consultations . •These centers must be prepared to provide information on management of any poison situation including household products, therapeutic drugs overdose, plants intoxication, envenomation with different venomous animals, etc. Drug Information Resources Tertiary: • Text books •Full-text computer data base •Review articles Secondary: • Indexed data • Abstracted data Primary: • Articles in medical journals Drug information: Is an information in text form or is a verbal information. Index data, medicus: Provide only bibliographic information that is indexed by topic. Abstracted data: Provide a brief description of information contained in a specific citation. Adverse event: Harm in the patient administered medication, but not necessarily caused by the medication. It's any injury caused by the drug. Adverse drug reactions: It's any adverse event associated with the usage of the drug Bioequivalent: the presence of 2 drugs the 1st is used as standard & the 2nd is compared with it in potency, side effect & ………….. Orphan drug status: drug used in treatment of rare diseases & the cost shouldn't cover the cost of the production & researches. Extemporaneous compounding: the compounding of drugs according to prescription. Formulary: It's continuously revised list of medication that are available for using within a hospital or institute OBRA: Omnibus Budget Reconciliation Act. It's a public law focused on drug benefits provided under medic aid & the law needs the pharmacist to: Conduct drug use information. Review utilisation of the drug. Review of the prescription to prevent drug interaction. i- Adverse Event or Adverse Drug Reactions Resources Adverse event: Harm in the patient administered medication, but not necessarily caused by the medication (all aspects of care, including diagnosis and treatment, failure to diagnose or treat, and the systems and equipment used to deliver care.. Adverse DRUG event: Harm caused by the use of a medication, may include adverse drug reaction OR medication error. Adverse DRUG reaction: Harm caused by the use of a medication at normal doses, unexpected e.g. CHF from metoprolol ii. Bioequivalence Resources Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards.Birkett 2003 “The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.“ FDA iii. Drug Interaction Resources iv. Drug Use in Renal Failure Resources v. Extemporaneous Compounding Resources the compounding of drugs according to prescription. • Extemporaneous Ophthalmic Preparations • Pediatric Drug Formulations •Remington’s Pharmaceutical Sciences vi. Identification Resources for Tablet and Capsule Imprint Codes vii. U.S. Drug Identification Resources (Merck Index) vii. Other Drug Identification Resources (BNF) viii. General Drug Information Resources (AHFS Drug Information: American Hospital Formulary Standards.) ix. Geriatric Dosing Resources: 1- Geriatric Dosage Handbook OBRA: Omnibus (collection, edition) Budget (financial statements, funds)Reconciliation (settlement, declaration) Act (work, action…). It's a public law focused on drug benefits provided under medic aid for all patients, specially geriatrics. x. Laboratory Tests xi. Medical Resources xii. Natural Product Resources xix Sterile Drug Product Resources xx- Drugs in Pregnancy and Lactation Resources xiii. Over-the-Counter Drug Resources xiv. Patient Counseling Resources xv. Pediatric Dosing Resources xvi. Pharmacology Resources xvii. Pharmacotherapy Resources xviii. Poison Control Information Resources II- Secondary Resources Indexed data covers Abstracted data Biomedical Journals Meetings • They Text books Other publications are available via on-line vendors, CD-ROM format or some systems as PubMed from the National Library of Medicine (<<http://www.nlm.nih.gov>>). 20 docsum 5 1 Recently Summary 10 Added (text) rosuvastatin and oxidative stress - Pu Results: 1 to 20 of 50 1. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. J Atheroscler Thromb. 2011;18(11):1018-28. Epub 2011 Sep 15. PMID: 21921413 [PubMed - in process] Free Article Related citations 2. Additive Effect of Homocysteine- and Cholesterol-Lowering Therapy on Endothelium-Dependent Vasodilation in Patients with Cardiovascular Disease. Wustmann K, Klaey M, Burow A, Shaw SG, Hess OM, Allemann Y. Cardiovasc Ther. 2011 Jul 31. doi: 10.1111/j.1755-5922.2011.00272.x. [Epub ahead of print] PMID: 21884007 [PubMed - as supplied by publisher] Related citations 3. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation. Solini A, Rossi C, Santini E, Madec S, Salvati A, Ferrannini E. J Hypertens. 2011 Oct;29(10):1930-9. PMID: 21881526 [PubMed - indexed for MEDLINE] Related citations J Atheroscler Thromb. 2011;18(11):1018-28. Epub 2011 Sep 15. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Source Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. [email protected] Abstract AIM: We aimed to assess the effects of rosuvastatin treatment on lipid levels, a biomarker of oxidative stress, albuminuria, and kidney function in patients with diabetic nephropathy. METHODS: We conducted a prospective, open-label, parallel group, controlled study of 104 patients with diabetic nephropathy, low-density lipoprotein cholesterol (LDL-C) levels of > 120 mg/dL, and well-controlled blood pressure who were undergoing treatment with renin angiotensin system inhibitors. Patients were randomly assigned to two groups: the rosuvastatin group (n = 52; 2.5 mg/day rosuvastatin, increased to 10 mg/day) and the control group (n = 52; no rosuvastatin administered). We determined the efficacy of rosuvastatin by monitoring serum lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde-modified LDL (MDA-LDL), and cystatin C levels. In addition, urinary albumin, 8-hydroxydeoxyguanosine (8-OHdG) and liver-type fatty acid-binding protein (L-FABP) levels were measured before and 6 months after rosuvastatin was added to the treatment. RESULTS: Rosuvastatin effectively reduced total cholesterol, LDL-C, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C) levels, and the LDL-C/ HDL-C ratio in the rosuvastatin group. These parameters remained unchanged in patients who were not treated with rosuvastatin. Although there was no significant change in the estimated glomerular filtration rate level, serum cystatin C levels and urinary albumin excretion rates were significantly decreased in the rosuvastatin group. In addition, rosuvastatin significantly reduced hs-CRP and MDA-LDL levels. Moreover, urinary 8-OHdG and L-FABP levels at baseline (13.5±5.1 and 41.7±26.1 ng/mgCr, respectively) decreased significantly at 6 months (11.5±4.0 and 26.9±13.4 ng/mgCr, respectively), and there was a significant correlation (r = 0.48, p < 0.01). Multivariate analysis revealed that albuminuria was significantly correlated with only rosuvastatin use (p = 0.0006, R(2)= 0.53). CONCLUSION: Rosuvastatin administration reduced albuminuria, oxidative stress, and serum cystatin C levels, independent of blood pressure and lipid levels. PMID: 21921413 [PubMed - in process] Free full text • Each Vendor provide access to numerous databases focused on a variety of areas such as current affairs, business and economics, social sciences and humanities, applied sciences and biosciences. • Cost of on-line access to secondary resources depends on the vendor, time of day the search is conducted, data base searched, citations printed, and other factors that vary with the service accessed. •Some examples of the 2ry resources: 1- Anti-infectives today: An indexing and abstracting service that summarizes current literature on drug therapy and management of infections. Available in newsletter and a variety of electronic formats. Published monthly. 2- BIOSIS Previews BIOSIS, Philadelphia. A major comprehensive resource that covers all areas of biological research, including the biomedical sciences. Meeting and conference citations include the basic sciences; may be more comprehensive than MEDLINE. 3- Index Medicus U.S. Government Printing Office, Washington, D.C. An index to the biomedical literature that references over 3000 journals. Note that this is a printed subset of MEDLINE. 4- MEDLINE National Library of Medicine, Bethesda, MD. One of the most expansive databases of biomedical information containing approximately 370,000 references. Citations from 1966 to the present can be searched for approximately 3500 journals. CDROM or via on-line services including the Internet as part of PubM <<http://www. nlm,nih.gov>>. Searching Computerized Databases • Consider the question to be researched. For example: Has diazepam been used rectally in pediatric patients for the management of status epilepticus? The question emphasizes four major points: (1) diazepam, (2) pediatric usage, (3) rectal administration, and status epilepticus. • Pediatrics = child = infants, etc…, so one term in service system may be another in other service systems . • For databases available through National Library of Medicine, index terms are called Medical Subject Headings or MESH terms. BOOLEAN OPERATORS are used to combine search terms. Three Boolean operators are used routinely: AND, OR, and NOT. In addition, some data bases have Boolean operators known as WITH and NEAR. III- Primary Literature • Consists of research studies published in biomedical journals, however, there are now some internet-only journals • Primary literature provides details of research methodology and scientific results that lead to therapeutic conclusions, and it is more up-to-date than 3ry resources . • 3ry and 2ry resources, however, consist of a review of published primary literature that may be biased or inaccurate, & one may get another conclusion from 1ry. Pre-publication Servers Electronic servers that publish non-reviewed research example: NetPrints (http://clinmed.netprints.org/home.dtl). The visitor is greeted by the following warning: “Articles posted on this site have not yet been accepted for publication by a peer reviewed journal. They are presented here mainly for the benefit of fellow researchers. Casual readers should not act on their findings, and journalists should be wary of reporting them”. An advantage of such servers is that negative results can be published. THANK YOU